Growth Factors Market

The Growth Factors Market is valued at USD 2.4 Bn in 2026 and is projected to reach USD 3.9 Bn, growing at a CAGR of 6% by 2033.

Quick Report Digest

1. The growth factor industry has a pivotal role in stem cell research as stem cell biologists are dependent on growth factors for proliferating the cells. The application of growth factors in stem cell research can create an avenue for a continuous supply of stem cells. Growth factors are thus inevitable for stem cell research.
2. The development of targeted delivery systems, such as nanoparticles and particles, for controlled release and site-specific delivery of growth factors, is enhancing the efficacy and bioavailability of these therapies while minimising off-target effects.
3. In 2023, the interleukins category dominated the industry in terms of value. As they are crucial for immune cell activation and differentiation, as well as cell growth, maturation, migration, and adhesion.
4. In terms of CAGR, the oncology application segment is expected to showcase excellent performance, attributing to potential role of growth factors in supporting cancer treatment modalities such as chemotherapy, and radiation therapy.
5. The segment of pharmaceutical and biotechnology companies is highly prevalent in the market for growth factors in terms of value. Pharmaceutical and biotechnology companies invest heavily in R&D to discover and develop new growth factors and growth factor-based therapies.
6. The North American region is anticipated to account for the highest value of the global growth factors market.

A Look Back and a Look Forward - Comparative Analysis

The growth factors market has seen significant growth over the past few decades, initially driven by the development of recombinant growth factors and their application in various therapeutic areas such as oncology, orthopedics, and wound healing. Over time, the indications for growth factors have expanded, with new therapeutic applications emerging in areas such as cardiovascular diseases, diabetes, neurodegenerative disorders, and tissue engineering.

The growth factors market is also, expected to continue its upward trajectory, driven by factors such as demographic changes, increasing disease burden, and advancements in biotechnology and healthcare infrastructure. The future of the growth factors market will likely see further expansion of therapeutic applications, with continued exploration of novel indications and combination therapies to address unmet medical needs and improve patient outcomes.

Key Growth Factors

• Increasing Focus on Oncology Research

Cytokines and growth factors are an important part of cancer research. The connection of growth factor families and oncogenes has led to a better understanding of carcinogenesis as well as providing new targets for chemotherapy. Growth factors are commonly engaged in the evolution of resistance to therapeutic strategies, extending polypeptide factors' significance to very late stages of tumor progression and opening new possibilities for cancer therapy.

Growth factors such as vascular epithelial growth factors, epidermal growth factors, fibroblast growth factors, and platelet-derived growth factors have an important role in cancer research and diagnosis. Cell Therapy & EX-vivo Manufacturing has also helped oncology research as cancer cells are more responsive to culture in vitro.

National Cancer Institute (NCI), along with other institutes, invests in major research initiatives to facilitate and support research on specific issues of importance to the cancer research enterprise. The National Cancer Institute Has Invested in initiatives such as Cancer Moonshot, the National Clinical Trials Network (NCTN), the NCI Genomic Data Commons (GDC), the RAS Initiative, and NCI Community Oncology Research Program (NCORP). The growing research and development funding in the field of oncology is expected to drive the growth of the global growth factors market.

• Important Role of Growth Factors in Wound Healing, and Skin Regeneration

Over the past few decades, there has been a noticeable rise in the number of individuals experiencing skin wounds, a trend that has significant implications for healthcare systems. A study published in Advances in Wound Care in March 2021 highlighted that chronic wounds impact the quality of life (QoL) for nearly 2.5% of the total population in the United States.

This not only affects individuals' wellbeing but also places a considerable economic burden on healthcare services. Consequently, effective wound management strategies have become paramount, encompassing both surgical and non-surgical interventions.

Among the non-surgical treatments, the application of exogenous growth factors (eGFs) has emerged as a crucial method for promoting wound healing or preparing wounds for surgical procedures. This approach has gained widespread recognition and is implemented in numerous countries.

Notably, the first successful use of commercial exogenous growth factors in treating wounds dates back approximately 30 years. Despite its relatively long history, there have been no reports of apparent toxicity or severe adverse reactions associated with the use of eGFs in wound management.

Major growth Barriers

• Stringent Regulatory Requirements for Product Approval

The growth factors market faces challenges due to stringent regulatory requirements for product approval, which can significantly impact the development and commercialisation of growth factor-based products for wound healing. These regulatory hurdles are put in place to ensure the safety and efficacy of these products for patients, but they can also slow down the process of bringing innovative treatments to the market.

Regulatory bodies such as the US FDA, and the European Medicines Agency (EMA) have strict guidelines and protocols for the approval of growth factor-based products. These requirements include extensive preclinical and clinical testing, which can be both time-consuming and costly. As a result, companies operating in the growth factors market must invest substantial resources in meeting these regulatory demands.

Growth factors have shown great promise in accelerating the healing process and improving patient outcomes. However, the stringent regulatory requirements for product approval can slow down the development and availability of these treatments, particularly for smaller companies and start-ups with limited resources.

• Restricted Demand for Growth Factors Due to High Costs

The growth factor market has experienced restricted demand due to the high cost associated with these factors and their role in wound healing. Growth factors are proteins that are crucial for cellular communication, proliferation, and differentiation and essential for tissue repair and regeneration. They often treat chronic wounds, burns, and other tissue injuries.

 Several factors contribute to the high cost of growth, including complex and expensive production processes, limited availability of raw materials, and the need for specialised equipment and expertise. These high costs have restricted demand for growth factor-based treatments, particularly in the healthcare sector, where budget constraints are a significant concern.

Growth factors have shown remarkable potential in wound healing, accelerating the healing process and improving patients' overall quality of life. However, their high cost has limited their widespread adoption, especially in low-income and developing countries.

Key Trends and Opportunities to Look at

1. Patent Expirations, and Generic Competition

Patent expirations and the subsequent entry of generic competitors can significantly impact the growth factor market. When patents expire, pharmaceutical companies lose their exclusive rights to manufacture and sell their products, allowing other companies to produce generic versions. This competition can lead to a decline in the original brand's market share and revenue. However, it also brings several advantages.

The increased competition often results in lower prices for the end-users, making growth factors more accessible to a broader patient population. Additionally, generic competitors may introduce new formulations or delivery systems to improve the efficacy and convenience of the growth factors, thus benefiting the overall growth of the market.

2. Inadequate Focus on GMP-Grade Products

Despite the presence of several large market players as well as multiple smaller companies, there are very limited companies that have a complete focus on being a provider of GMP-grade products and reagents. Different manufacturers have different specialisations and product offerings, with most large companies combining research products, biologics, recombinant proteins, and reagents with equipment, and in-vitro diagnostics tools.

Exclusive focus on this market ensures a better quality of products, customer loyalty, and an established distribution network that can cater to product availability around the globe. R&D spending on life sciences is one of the largest among all other sectors and is expected to grow at a stable rate over the next several years. Companies investing in providing tools and products to cater to research and manufacturing requirements can expect to see stable returns.

How Does the Regulatory Scenario Shape this Industry?

In Europe and the European Union, marketing authorisation and applications for all biotechnology-derived medicinal products, are reviewed by a central association called the European Medicines Agency (EMA). The European Commission grants the Decisions about concerning the authorisation of these biotechnology medicinal products based on the scientific opinions of the EMA. Whatever the EMA decides about marketing authorisation is valid in all EU Member States.

Whereas, in India, the DCGI is responsible for approvals of all biotechnology-based products that are in the pre-clinical and clinical trial phases. DCGI also regulates new drug applications and the importation of drugs from abroad for pharmaceutical and biologics.

The regulatory approval process for biotech products (those synthesized by recombinant DNA (r-DNA) technology) differs from that of standard medicinal products. In the case of biological products, however, additional approvals are required.

Fairfield’s Ranking Board

Top Segments

1. Interleukins Category Continues to Dominate

Interleukins, a group of cytokines produced by immune cells, play a significant role in the growth factors market. They regulate various cellular activities, including proliferation, differentiation, and immune response modulation.

In the context of the growth factors market, interleukins often act as mediators or enhancers of growth factor signalling pathways, amplifying their effects on target cells. For example, interleukin-2 (IL-2) enhances the proliferation and activation of T cells, synergizing with growth factors like granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunotherapy approaches for cancer treatment.

2. Cell Therapy and Ex-Vivo Manufacturing Application Spearheads

Cell therapy and ex vivo manufacturing play crucial roles in the growth factors market by leveraging growth factors to enhance the effectiveness of therapeutic interventions. Cell therapy involves the transplantation or manipulation of cells to restore, repair, or replace damaged tissues or organs.

Growth factors are instrumental in supporting the expansion, differentiation, and functionality of cells used in cell therapy, such as stem cells or immune cells. They help optimise cell culture conditions, promote cell survival, and guide cellular processes to achieve desired therapeutic outcomes.

3. Pharma and Biotech Companies at the Forefront of Adoption

Pharmaceutical and biotechnology companies are pivotal in driving growth and innovation in the growth factors market. These companies invest heavily in research and development to discover and develop new growth factors and growth factor-based therapies. Through rigorous preclinical studies and clinical trials, they assess the safety and efficacy of these therapies across various disease indications, ranging from oncology to regenerative medicine.

Additionally, pharmaceutical and biotechnology firms play a crucial role in product development and commercialisation, undertaking the manufacturing, quality control, and regulatory approval processes necessary to bring growth factor therapies to market.

Regional Frontrunners

North America Extends the Largest Revenue Contribution

North America faces a high prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes. Growth factors play a critical role in the treatment and management of these conditions, driving demand for growth factor therapies.

The region is home to a robust biotechnology and pharmaceutical industry with significant investments in research and development. Technological advancements in biotechnology, including gene editing, tissue engineering, and recombinant DNA technology, have led to the development of innovative growth factor-based therapies.

Asia Pacific Witnesses Growing Interest in Growth Factors as an Effective Treatment Alternative

Asia Pacific countries are making significant investments in biotechnology research and development, leading to advancements in the understanding of molecular pathways, and the development of novel growth factor-based therapies for various medical conditions.

The Asia Pacific region is witnessing a surge in the incidence of chronic diseases, including cancer, cardiovascular diseases, and diabetes, due to changing lifestyles, dietary habits, and environmental factors, creating a growing need for effective treatment options such as growth factors.

Fairfield’s Competitive Landscape Analysis

The global market for growth factors is consolidated, with fewer significant companies present worldwide. To increase their global footprint, the major firms are launching new items and enhancing their distribution networks. In addition, Fairfield Market Research anticipates that during the next few years, there will be further market consolidation.

Who are the Leaders in the Global Growth Factors Market Space?

1. Lonza Group AG
2. Thermo Fisher Scientific Inc.
3. Merck KGaA
4. Hoffmann-La Roche Ltd.
5. Applied Biological Materials (abm), Inc.
6. Abcam plc
7. GE Healthcare
8. Cell Signaling Technology, Inc.
9. Meridian Bioscience Inc.
10. Sartorius CellGenix GmbH
11. Bio-Techne Corporation
12. Proteintech Group, Inc.
13. Miltenyi Biotec
14. Creative Bioarray
15. Akron Biotech
16. Sino Biological Inc.
17. Repligen corporation
18. LEADGENE BIOMEDICAL, INC.
19. PeproTech Inc.

An Expert’s Eye

Demand and Future Growth

The rising incidence of chronic diseases such as cancer, cardiovascular diseases, and diabetes is driving demand for growth factors to support tissue repair, regeneration, and therapeutic interventions. Also, technological advancements in biotechnology, such as gene editing, CRISPR/Cas9, and next-generation sequencing, are driving demand for novel growth factor therapies tailored to specific genetic and molecular targets.

Supply Side of the Market

According to our analysis, the continued innovation in biotechnology and biopharmaceuticals is driving the development of novel growth factors and growth factor-based therapies with improved efficacy, specificity, and safety profiles.

Global Growth Factors Market is Segmented as Below:

By Product Type:

• Transforming Growth Factor (TGF)
  • Activin
  • Bone Morphogenetic Proteins (BMPs)
  • TGF-beta Proteins
• Epidermal Growth Factors (EGFs)
• Platelet-Derived Growth Factors (PDGFs)
• Fibroblast Growth Factors (FGFs)
• Insulin-like Growth Factors (IGFs)
• Vascular Endothelial Growth Factors (VEGFs)
• Hepatocyte Growth Factors (HGFs)
• Tumor Necrosis Factors (TNFs)
• Interleukins 
• Others

By Application:

• Oncology
• Hematology
• Wound Healing
• Dermatology
• Cardiovascular Disease & Diabetes
• Cell Therapy and Ex-Vivo Manufacturing
• Others

By End User:

• Pharmaceutical and Biotechnology Companies
• Research Centres & Academic Institutes
• Contract Research Organisations

By Geographic Coverage:

• North America 
• Europe 
• Asia Pacific 
• Latin America 
• Middle East & Africa